Previous Close | 102.00 |
Open | 102.37 |
Bid | 101.29 x 400 |
Ask | 101.44 x 400 |
Day's Range | 100.45 - 103.79 |
52 Week Range | 62.55 - 142.82 |
Volume | |
Avg. Volume | 3,775,035 |
Market Cap | 38.828B |
Beta (5Y Monthly) | 1.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -12.33 |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 132.36 |
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.